Physician profile
Ciel Harris
NPI 1083097869
$1,263.34
in general payments reported to CMS, 2019-2025
18 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2021: $49.64 · 2022: $243 · 2023: $243 · 2024: $391 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $471.85 | 2021-2025 | |
| Gilead Sciences, INC. | $105.06 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.04 | 2021-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $89.60 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $77.63 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $52.66 | 2023 | Entyvio |
| Ardelyx, INC. | $47.99 | 2025 | Ibsrela |
| Boston Scientific Corporation | $41.85 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Organon LLC | $38.65 | 2023-2024 | Renflexis, Hadlima |
| Janssen Biotech, INC. | $38.12 | 2024 | Stelara |
| Mallinckrodt Hospital Products INC. | $35.93 | 2023 | Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $33.48 | 2022 | |
| Merck Sharp & Dohme LLC | $29.24 | 2024 | Dificid |
| Pfizer INC. | $25.74 | 2023 | |
| Ironwood Pharmaceuticals, INC | $25.49 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $23.24 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $17.19 | 2024 | |
| Redhill Biopharma INC. | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ciel Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.